Back to catalog

Nephrology

Acute Interstitial Nephritis Risk calculator

Enter the published formula inputs below to calculate and interpret this score.

Clinical inputs

mg/dL

Allowed range: 0.2–20 mg/dL

Quick picks

The natural log uses mg/dL. A value entered in µmol/L is divided by 88.4.

mg/dL

Allowed range: 1–200 mg/dL

Quick picks

Enter BUN in mg/dL. Urea in mmol/L is multiplied by 2.801. The model uses the ratio of this BUN to creatinine in mg/dL.

Allowed range: 1.001–1.04

Quick picks

Dipstick specific gravity, such as 1.010. Each 0.001 above 1.000 lowers the logit.

Urine dipstick protein

0 or 1+ adds 0.9360127 to the logit. 2+ or higher adds nothing.

Result

4 fields remaining

Anyone can run this calculator. Sign in to save, favourite, or send the result.

Ruqelo is AI and can make mistakes. Check important information.

Clinical inputs

  • Serum creatinine before biopsy (mg/dL)Accepted range: 0.2 to 20
  • Blood urea nitrogen (mg/dL)Accepted range: 1 to 200
  • Urine dipstick specific gravityAccepted range: 1.001 to 1.04
  • Urine dipstick protein

Primary source

Moledina DG et al. Development and external validation of a diagnostic model for biopsy-proven acute interstitial nephritis using electronic health record data. Nephrol Dial Transplant. DOI: 10.1093/ndt/gfab346. PMID: 34865148. Table 4 odds ratios and the printed intercept 0.770398. Development-cohort weights, read from the later validation supplement that reprints them: logit = 0.8367518 × ln(creatinine in mg/dL) − 0.9181938 × ln(BUN/creatinine) − 0.0501203 × (specific gravity − 1) × 1000 + 0.9360127 if dipstick protein is 0 or 1+, otherwise 0, + 0.770398. Probability = exp(logit) / (1 + exp(logit)). Urea in mmol/L is multiplied by 2.801 to reach BUN in mg/dL. Table 5 in the external biopsy cohort: at 5% sensitivity 0.94 and specificity 0.32; at 10% sensitivity 0.71 and specificity 0.63; at 25% sensitivity 0.27 and specificity 0.94. This is the development intercept, not the later prevalence shift of ln(local prevalence / 0.23). (2022)

View source